Study of Omalizumab in Moderate to Severe Bronchial Asthma
This study has been completed.
Daiichi Sankyo Co., Ltd.
Information provided by:
First received: October 3, 2005
Last updated: October 24, 2011
Last verified: October 2011
This study will evaluate the safety and efficacy of omalizumab up to 16 weeks in adult patients with moderate to severe bronchial asthma.
|Study Design:||Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
|Official Title:||Study of Omalizumab in Moderate to Severe Bronchial Asthma|
Resource links provided by NLM:
Further study details as provided by Novartis:
Primary Outcome Measures:
- Morning peak expiratory flow (PEF) at baseline and end of treatment.
Secondary Outcome Measures:
- Pulmonary function parameters measured by spirometer
- Frequency of rescue medication use
- Symptom score
- Activities of daily living score
- Nighttime sleep score
|Study Start Date:||October 2002|
|Study Completion Date:||May 2005|
|Primary Completion Date:||May 2005 (Final data collection date for primary outcome measure)|
Contacts and Locations